Supernus, Inc (SUPN)

Currency in USD
26.63
-0.12(-0.43%)
Real-time Data·
High dividend Yield
SUPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.1626.74
52 wk Range
21.4833.22
Key Statistics
Prev. Close
26.74
Open
26.58
Day's Range
26.16-26.74
52 wk Range
21.48-33.22
Volume
483.86K
Average Volume (3m)
2.54M
1-Year Change
7.6906%
Book Value / Share
-0.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SUPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
49.50
Upside
+85.88%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Supernus, Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 49.50
(+85.88% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Buy45.00+69.56%43.00MaintainOct 28, 2026
Barclays
Buy43.00+62.02%46.00MaintainAug 05, 2026
Barclays
Buy46.00+73.32%-New CoverageJun 18, 2026
Jefferies
Buy50.00+88.39%45.00MaintainApr 30, 2026
H.C. Wainwright
Buy48.00+80.86%35.00MaintainJan 12, 2026

Supernus, Inc Earnings Call Summary for Q2/2026

  • Supernus and Indivior beat Q2 2026 estimates with EPS of $1.15 vs. $0.74 forecast and revenue of $343M vs. $284.9M, up 55.4% and 20.4% respectively.
  • Companies announced all-stock merger creating CNS-focused drugmaker with $2.2B annual revenue, $888M adjusted EBITDA, and $125M expected cost synergies.
  • Combined entity to maintain four sales forces across ADHD, Parkinson's, women's health, and addiction; merger expected to close Q4 2026 pending approvals.
  • SUBLOCADE holds 76% share of long-acting injectable OUD market with record patient starts; Qelbree cited as fastest-growing ADHD brand driving momentum.
  • Pro forma company shows 41% adjusted EBITDA margin with $878M net debt; Indivior shares down 1.22% to $39.52 despite strong results and strategic rationale.
Last Updated: 2026-08-03, 09:40 a/m
Read Full Transcript

Earnings

Latest Release
Oct 29, 2026
EPS / Forecast
1.32 / 0.80
Revenue / Forecast
356M / 291.63M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 3.69
Dividend Yield
30.40%
Industry Median 2.16%
Annualized payout
8.13
Paid unevenly
5-Years Growth
-
Growth Streak

SUPN Income Statement

Compare SUPN to Peers and Sector

Metrics to compare
SUPN
Peers
Sector
Relationship
P/E Ratio
12.3x−0.9x−0.2x
PEG Ratio
0.05−0.010.00
Price/Book
−92.6x1.7x2.6x
Price / LTM Sales
4.0x3.2x2.8x
Upside (Analyst Target)
108.8%63.0%62.1%
Fair Value Upside
Unlock9.9%9.5%Unlock

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Supernus, Inc. was formerly known as Indivior Pharmaceuticals, Inc. and changed its name Supernus, Inc. in November 2026. Supernus, Inc. was incorporated in 2014 and is headquartered in Rockville, Maryland.

Employees
833

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
54.05M45.80%1.52B
Other Institutional Investors
80.20M54.20%2.26B
Public Companies & Retail Investors
0.000.00%0.00
Total
134.25M100.00%3.79B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15.85%18,709,432527,793
Vanguard Portfolio Management, LLC6.42%7,572,287213,614

People Also Watch

34.09
VSNT
+0.26%
59.36
ATRC
-3.13%
91.13
HLNE
+1.11%
259.23
MYRG
+5.13%

FAQ

What Is the Supernus, Inc (SUPN) Stock Price Today?

The Supernus, Inc stock price today is 26.63 USD.

What Stock Exchange Does Supernus, Inc Trade On?

Supernus, Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Supernus, Inc?

The stock symbol for Supernus, Inc is "SUPN."

Does Supernus, Inc Pay Dividends? What’s The Current Dividend Yield?

The Supernus, Inc dividend yield is 30.4%%.

What Is the Supernus, Inc Market Cap?

As of today, Supernus, Inc market cap is 5.55B USD.

What Is Supernus, Inc's Earnings Per Share (TTM)?

The Supernus, Inc EPS (TTM) is 3.69.

From a Technical Analysis Perspective, Is SUPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Supernus, Inc Stock Split?

Supernus, Inc has split 0 times.

How Many Employees Does Supernus, Inc Have?

Supernus, Inc has 833 employees.

What is the current trading status of Supernus, Inc (SUPN)?

As of Nov 06, 2026, Supernus, Inc (SUPN) is trading at a price of 26.63 USD, with a previous close of 26.74 USD. The stock has fluctuated within a day range of 26.16 USD to 26.74 USD, while its 52-week range spans from 21.48 USD to 33.22 USD.

What Is Supernus, Inc (SUPN) Price Target According to Analysts?

The average 12-month price target for Supernus, Inc is 49.50 USD, with a high estimate of 53 USD and a low estimate of 45 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +85.88% Upside potential.

What Is the SUPN Premarket Price?

SUPN's last pre-market stock price is 26.64 USD. The pre-market share volume is 1,090.00, and the stock has decreased by -0.10, or -0.37%.

What Is the SUPN After Hours Price?

SUPN's last after hours stock price is 27.19 USD, the stock has decreased by 0.45, or 1.68%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.